Here we determine synergistic combinations with ibrutinib or ONO-7790500 a highly specific ITK inhibitor, and report potential enhancement of activity to be taken forward in further pre-clinical testing in mouse models of T-cell lymphoma. Here, ITK is linked to T-cell non-Hodgkin lymphoma.